Lupus Nephritis – Our Core Strategic Focus
Our lead drug, voclosporin, is an immunosuppressant that has utility across many indications. Although voclosporin has been shown to be effective in indications such as prevention of rejection in renal transplantation, it is the lupus market where our company’s key focus now lies. Kidney Inflammation caused by Systemic Lupus Erythematosus (SLE) is referred to as lupus nephritis (LN), and it is estimated that approximately 40-50% of all SLE patients have clinical LN requiring treatment. In patients with LN, renal damage results in proteinuria and/or hematuria and a decrease in renal function as evidenced by reduced estimated glomerular filtration rate (eGFR), and increased serum creatinine levels. Poorly controlled LN can lead to permanent and irreversible tissue damage within the kidney, resulting in end-stage renal disease (ESRD), thus making LN a serious and potentially life-threatening condition.